TABLE 3.
Univariate analysis for clinical factors, therapeutic issues, and laboratory findings in surviving versus non‐surviving patients in ICU.
| Non‐survivors N = 88 (%) | Survivors N = 262 (%) | Relative risk | 95% CI | P value | |
|---|---|---|---|---|---|
| Age >65 years | 46/88 (52.3%) | 88/262 (33.6%) | 1.55 | 1.18–2.0 | 0.002 |
| Male/female | 51/37 | 154/108 | 0.9 | 0.79–1.19 | 0.9 |
| Obesity BMI > 30 | 18/53 (34%) | 59/145 (40.6%) | 0.8 | 0.49–1.3 | 0.41 |
| Smoking habits | 38/88 (43.2%) | 132/262 (50.5%) | 0.8 | 0.55–1.15 | 0.26 |
| COPD | 18/86 (20.9%) | 57/259 (22%) | 0.95 | 0.59–1.46 | 0.88 |
| OSA | 8/87 (9.2%) | 38/261 (14.5%) | 0.66 | 0.33–1.21 | 0.27 |
| Asthma | 6/87 (6.9%) | 57/262 (21.7%) | 0.33 | 0.15–0.69 | 0.0012 |
| Diabetes mellitus | 32/88 (36.4%) | 98/260 (37.7%) | 0.95 | 0.65–1.38 | 0.89 |
| Hypertension | 38/88 (42.7%) | 142/262 (54%) | 0.71 | 0.49–1.02 | 0.07 |
| Coronary disease | 22/84 (26.1%) | 47/259 (18.2%) | 1.4 | 0.92–2.1 | 0.11 |
| Alcohol abuse | 16/88 (18.2%) | 59/262 (22.5%) | 0.81 | 0.49–1.28 | 0.45 |
| Liver cirrhosis | 5/87 (5.75%) | 8/262 (3.1%) | 1.56 | 0.71–2.76 | 0.32 |
| Chronic dialysis | 5/88 (5.7%) | 8/262 (3%) | 1.55 | 0.7–2.72 | 0.32 |
| History of cancer | 17/88 (19.3%) | 23/261 (8.8%) | 1.85 | 1.87–2.7 | 0.011 |
| Immunosuppression | 6/88 (6.8%) | 10/260 (3.85%) | 1.51 | 0.73–2.6 | 0.24 |
| Pregnancy (females <41 years) | 3/6 (50%) | 10/21 (47.6%) | 1.07 | 0.28–4 | 1 |
| Duration of stay >10 days | 32/88 (36.4%) | 101/262 (38.5%) | 0.93 | 0.63–1.35 | 0.79 |
| SAPS II score >40 | 71/84 (77.2%) | 101/261 (38.7%) | 4.81 | 2.91–8.1 | < 0.001 |
| Intubation within 48 h | 68/88 (77.2%) | 117/262 (44.7%) | 3 | 1.95–4.78 | < 0.0001 |
| Intubation during stay | 74/88 (84.1%) | 130/262 (49.6%) | 3.78 | 2.66–6.44 | 0.0001 |
| MV > 14 days | 25/74 (33.8%) | 46/129 (36.6%) | 0.94 | 0.63–1.37 | 0.87 |
| Vaso‐support drugs within 48 h | 66/82 (80.5%) | 109/258 (42.3%) | 3.89 | 2.38–6.44 | < 0.0001 |
| ARDS | 61/82 (74.4%) | 73/251 (29.8%) | 4.31 | 2.79–6.73 | < 0.0001 |
| ECMO | 21/88 (23.8%) | 6/262 (2.3%) | 3.75 | 2.68–4.92 | < 0.0001 |
| Dialysis (except previous chronic dialysis) | 39/81 (48.2%) | 25/254 (9.8%) | 3.93 | 2.78–5.5 | < 0.0001 |
| Vaccination | 1/55 (6.7%) | 15/65 (23.1%) | 0.29 | 0.0064–2.2 | 0.29 |
| Oseltamivir Administration | 48/85 (56.5%) | 181/260 (69.6%) | 0.65 | 0.45–0.95 | 0.03 |
| H1N1 | 38/88 (43.2%) | 115/262 (43.9%) | 0.97 | 0.67–1.4 | 0.99 |
| Bacterial concomitant infection | 38/84 (45.2%) | 78/240 (32.5%) | 1.43 | 1.2–2.05 | 0.04 |
| Pneumococcus vs. non‐concomitant infection | 7/53 (13.2%) | 21/183 (11.5%) | 1.17 | 0.4–3.1 | 0.8 |
| Staphylococcus aureus vs. non‐concomitant infection | 13/53 (24.5%) | 27/189 (14.2%) | 1.67 | 0.7–3.7 | 0.16 |
| Leucocytes <2.5 G/L | 12/88 (13.6%) | 11/259 (4.3%) | 2.24 | 1.35–3.24 | 0.005 |
| Hemoglobin <8 g/dL | 8/88 (9.1%) | 8/259 (3.1%) | 2.06 | 1.13–3.17 | 0.03 |
| Platelet <50 G/L | 5/88 (5.6%) | 3/259 (1.2%) | 2.55 | 1.22–3.8 | 0.02 |
| CRP >100 mg/L | 26/39 (66.7%) | 82/163 (50.3%) | 1.74 | 0.96–3.18 | 0.07 |